AgeX credit running out with substantial doubt it can continue
FierceBiotech - 15-Aug-2022Let's hope their research is either successful for the company or its successors
Join the club for FREE to access the whole archive and other member benefits.
Biotechnology company focused on the development of novel therapeutics for age-related degenerative disease
AgeX is a biotechnology company focused on the development of novel therapeutics for age-related degenerative disease. AgeX’s mission is to apply the proprietary technology platform related to telomerase-mediated cell immortality and regenerative biology to address a broad range of diseases of aging. The current preclinical development efforts include two cell-based therapies derived from telomerase-positive pluripotent stem cells and two product candidates derived from the company’s proprietary induced Tissue Regeneration (iTR™) technology. AGEX-BAT1 and AGEX-VASC1 are cell-based approaches in the preclinical stage of development comprised of young regenerative cells modified using AgeX’s UniverCyte™ technology facilitating immune tolerance, formulated in HyStem® matrix, designed to correct metabolic imbalances in aging and to restore vascular support in ischemic tissues respectively. AGEX-iTR1547 is a drug-based formulation in preclinical development intended to restore regenerative potential in a wide array of aged tissues afflicted with degenerative disease using the company’s proprietary iTR technology.
Key highlights
March-2023: Received a $10,000,000 loan from Juvenescence to acquire Serina Therapeutics Inc. Plans to spinoff of its subsidiary Reverse Bioengineering. Michael West stepping down as CEO of AgeX but will continue as CEO of Reverse Bio.
Visit website: https://www.agexinc.com/
Details last updated 02-Oct-2019
Let's hope their research is either successful for the company or its successors
Both companies to continue with the diverse technologies and product development
He believes in the importance of boosting immunoresilience among elderly
Scientists created stem cells from supercentenarian for the first time, calling it "super sauce"
Evidence of cellular age reversal demonstrated in this gateway research
When some of these succeed in human trials even more money will pile in to fund further advances
New reprogramming technology could provide an alternate source of material needed for therapies
May only be a few years away from implementing induced tissue regeneration in humans
It powers foetal development and telomere length, but also cancers
Good summary of some major investments in life extension companies
Once proven in mice, demand and funding will surge
Study that reveals genes implicated in tissue regeneration, cancer, and aging. Worked in collabo...